Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer
BackgroundFollicle-stimulating hormone (FSH) dysregulation plays a potential role in prostate cancer progression. The objective of this study was to evaluate whether higher FSH levels during androgen deprivation therapy (ADT) for recurrent prostate cancer could predict the development of castration-...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/view/171/101 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849764370186240000 |
|---|---|
| author | Kaleem Atchia France-Hélène Joncas Lily Summers Trasiewicz Wei Phin Tan Keyue Ding Brant A. Inman Paul Toren |
| author_facet | Kaleem Atchia France-Hélène Joncas Lily Summers Trasiewicz Wei Phin Tan Keyue Ding Brant A. Inman Paul Toren |
| author_sort | Kaleem Atchia |
| collection | DOAJ |
| description | BackgroundFollicle-stimulating hormone (FSH) dysregulation plays a potential role in prostate cancer progression. The objective of this study was to evaluate whether higher FSH levels during androgen deprivation therapy (ADT) for recurrent prostate cancer could predict the development of castration-resistant prostate cancer (CRPC), prostate cancer-specific survival (CSS), and overall survival (OS).
MethodsSerum FSH levels were measured in cryopreserved samples of the continuous ADT arm of the PR.7 trial, supplemented with analogous samples from a large contemporaneous biobank. Univariate and multivariate analyses assessed the relationship between FSH tertiles and time to CRPC, as well as CSS, and OS.
ResultsA total of 172 patients were included in our analysis. Of these, 54 patients (31%) developed CRPC during the 9-year follow-up. Median FSH for the tertiles was 4.35, 6.13, and 11.32 mIU/mL. FSH tertiles were not significantly associated with the time to CRPC, or with CSS or OS. FSH levels were not a significant prognostic factor for these oncologic outcomes.
ConclusionAs previously reported, the use of gonadotropin-releasing hormone (GnRH) antagonists for ADT has significantly more suppression of FSH levels than GnRH agonists. Our results do not suggest that differences in circulating FSH 1 year following ADT initiation influence long-term oncologic outcomes or development of CRPC. |
| format | Article |
| id | doaj-art-c6d5d6a3d9a147708ed505ea15760e66 |
| institution | DOAJ |
| issn | 2563-6499 |
| language | English |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Société Internationale d’Urologie Journal |
| spelling | doaj-art-c6d5d6a3d9a147708ed505ea15760e662025-08-20T03:05:09ZengMDPI AGSociété Internationale d’Urologie Journal2563-64992022-03-0132566110.48083/LWHQ7760Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate CancerKaleem AtchiaFrance-Hélène JoncasLily Summers TrasiewiczWei Phin TanKeyue DingBrant A. InmanPaul TorenBackgroundFollicle-stimulating hormone (FSH) dysregulation plays a potential role in prostate cancer progression. The objective of this study was to evaluate whether higher FSH levels during androgen deprivation therapy (ADT) for recurrent prostate cancer could predict the development of castration-resistant prostate cancer (CRPC), prostate cancer-specific survival (CSS), and overall survival (OS). MethodsSerum FSH levels were measured in cryopreserved samples of the continuous ADT arm of the PR.7 trial, supplemented with analogous samples from a large contemporaneous biobank. Univariate and multivariate analyses assessed the relationship between FSH tertiles and time to CRPC, as well as CSS, and OS. ResultsA total of 172 patients were included in our analysis. Of these, 54 patients (31%) developed CRPC during the 9-year follow-up. Median FSH for the tertiles was 4.35, 6.13, and 11.32 mIU/mL. FSH tertiles were not significantly associated with the time to CRPC, or with CSS or OS. FSH levels were not a significant prognostic factor for these oncologic outcomes. ConclusionAs previously reported, the use of gonadotropin-releasing hormone (GnRH) antagonists for ADT has significantly more suppression of FSH levels than GnRH agonists. Our results do not suggest that differences in circulating FSH 1 year following ADT initiation influence long-term oncologic outcomes or development of CRPC.https://siuj.org/index.php/siuj/article/view/171/101follicle-stimulating hormonebiomarkerandrogen deprivation therapyoncologic outcomesprostate cancer |
| spellingShingle | Kaleem Atchia France-Hélène Joncas Lily Summers Trasiewicz Wei Phin Tan Keyue Ding Brant A. Inman Paul Toren Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer Société Internationale d’Urologie Journal follicle-stimulating hormone biomarker androgen deprivation therapy oncologic outcomes prostate cancer |
| title | Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer |
| title_full | Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer |
| title_fullStr | Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer |
| title_short | Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer |
| title_sort | follicle stimulating hormone levels during androgen deprivation therapy are not associated with survival or development of castration resistant prostate cancer |
| topic | follicle-stimulating hormone biomarker androgen deprivation therapy oncologic outcomes prostate cancer |
| url | https://siuj.org/index.php/siuj/article/view/171/101 |
| work_keys_str_mv | AT kaleematchia folliclestimulatinghormonelevelsduringandrogendeprivationtherapyarenotassociatedwithsurvivalordevelopmentofcastrationresistantprostatecancer AT francehelenejoncas folliclestimulatinghormonelevelsduringandrogendeprivationtherapyarenotassociatedwithsurvivalordevelopmentofcastrationresistantprostatecancer AT lilysummerstrasiewicz folliclestimulatinghormonelevelsduringandrogendeprivationtherapyarenotassociatedwithsurvivalordevelopmentofcastrationresistantprostatecancer AT weiphintan folliclestimulatinghormonelevelsduringandrogendeprivationtherapyarenotassociatedwithsurvivalordevelopmentofcastrationresistantprostatecancer AT keyueding folliclestimulatinghormonelevelsduringandrogendeprivationtherapyarenotassociatedwithsurvivalordevelopmentofcastrationresistantprostatecancer AT brantainman folliclestimulatinghormonelevelsduringandrogendeprivationtherapyarenotassociatedwithsurvivalordevelopmentofcastrationresistantprostatecancer AT paultoren folliclestimulatinghormonelevelsduringandrogendeprivationtherapyarenotassociatedwithsurvivalordevelopmentofcastrationresistantprostatecancer |